Belagenpumatucel-L, a therapeutic vaccine comprised of four TGF-β2 antisense gene-modified allogeneic NSCLC cell lines was assessed in grade III/IV NSCLC patients. This evidence concerns the gene TGFB2 and non-small cell lung carcinoma.